Imaging News and Research

RSS

Cintas issues tips for maintaining secure, compliant EMRs

According to the 2010 Healthcare Information and Management Systems Society (HIMSS) Analytics Report: Security of Patient Data, the number of healthcare organizations that reported a breach in data security increased by 6 percent in 2010, totaling 19 percent. As more healthcare organizations migrate to electronic medical records (EMRs), it's important to take the proper steps to reduce risk and prevent medical liability suits.

14 Jun 2010

McDermott's Health Industry Advisory Practice Group recognized as Health Team of the Year

McDermott Will & Emery is pleased to announce the Firm's Health Industry Advisory Practice Group was honored as the "Health Team of the Year" during the Chambers USA Awards in New York on June 10, 2010. This is the first time an award in this category has been given on a national basis by Chambers, and McDermott was selected over four other finalist firms.

14 Jun 2010

TF12 antibody targets EGP-1 expressed in epithelial cancer: Immunomedics

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that TF12, in combination with radiolabeled peptides, produced specific, fast, high-contrast imaging and pretargeted radioimmunotherapy of epithelial cancers that include cancers of the prostate and the ovary.

14 Jun 2010

Evidence-based review of TBI in sport

Experts from Johns Hopkins Medicine hosted a press conference following a continuing medical education program on the epidemiology of head injury in professional football. The program was an evidence-based review of traumatic brain injury in the sport.

14 Jun 2010

Children get MRI tests for reasons unrelated to benign anomalies: Study

Pediatricians whose patients undergo "routine" brain MRIs need a plan to deal with findings that commonly reveal unexpected-but-benign anomalies that are unlikely to cause any problem, reports a research team led by Johns Hopkins Children's Center investigators.

14 Jun 2010

National MS Society commits over $2.4M to support 7 CCSVI research projects

Over $2.4 million has been committed by the National MS Society (USA) and the MS Society of Canada to support 7 new research projects focusing on the role of CCSVI in MS.

14 Jun 2010

Olfactory function tests could help in treating patient in early stages of PD

A fast, simple and non invasive test of the ability to smell may be an important tool to screen people who are likely to develop Parkinson's disease, in which motor symptoms only become evident at a later stage of the disease, a German scientist will tell the annual conference of the European Society of Human Genetics today (Saturday).

14 Jun 2010

HL survivors do not receive recommended cancer screening tests: Study

A population-based study of 2,071 Hodgkin lymphoma survivors over 15 years has discovered that while many survivors had multiple X-rays and CT scans years after treatment was finished, they often did not receive recommended cancer screening tests.

11 Jun 2010

UT Southwestern first in North Texas to use dual-console DaVinci Surgical System

Physicians at UT Southwestern Medical Center are the first in North Texas to use the newest generation surgical robot, the dual-console DaVinci Surgical System, enabling them to perform minimally invasive surgeries with even greater precision.

11 Jun 2010

Protein IL-10 removes Escherichia coli K1 bacterium from blood and reverses brain damage

A team of researchers at Childrens Hospital Los Angeles (CHLA), along with colleagues from the Keck School of Medicine of the University of Southern California and the Universite Auvergne, France, have discovered an important role for a small, naturally occurring protein called interleukin-10 (IL-10) in removing bacteria from the blood of infected mice and reversing damage to the brain.

11 Jun 2010

SBUMC uses RapidArc radiotherapy technology to treat cancer patients

A breakthrough external beam radiotherapy technology that is fast, precise, and has optimal dose delivery to targeted tumors while limiting damage to surrounding normal tissue, is the latest radiotherapy weapon that cancer specialists are using at Stony Brook University Medical Center to treat patients.

11 Jun 2010

New study demonstrates link between smoking and flat adenomas

According to a new study, smoking was found to have a strong association with the presence of flat adenomas (precancerous polyps) in the colon and may explain the earlier onset of colorectal cancer in smokers, as well as the advanced stage with which they present when compared to nonsmokers. Flat adenomas are more difficult to detect and have more aggressive pathology than the typical raised type of polyp detected during colorectal cancer screening.

11 Jun 2010

DZNE, MRC and CIHR sign cooperation agreement for research on neurodegenerative diseases

Representatives of the German Centre for Neurodegenerative Diseases, the UK Medical Research Council and the Canadian Institutes of Health Research today signed a cooperation agreement that aims to establish and apply harmonised guidelines and technologies for research on neurodegenerative diseases.

11 Jun 2010

Merge Healthcare launches CIMS workflow solution for imaging in clinical trials

Merge Healthcare has combined its expertise in medical imaging and clinical trials management software to launch a complete workflow solution for imaging in clinical trials. The new CIMS solution is the first open platform in the industry that allows organizations involved in clinical trials to transparently execute the imaging portion of the study within the overall electronic trial management solution.

11 Jun 2010

Spectrum Dynamics commences ultra low dose trials of radiopharmaceutical agents with D-SPECT technology

Cardiovascular imaging accounts for 30 percent of all the radiation patients receive in the U.S. and today, at the Society for Nuclear Medicine annual meeting, Spectrum Dynamics announced it has begun clinical studies to show that its D-SPECT™ technology can accommodate significantly lower doses of radiopharmaceutical agents so the total radiation exposure to patients and staff is much lower compared to conventional cardiac imaging.

10 Jun 2010

New study finds propofol poses low risk for children undergoing research-driven imaging studies

A new study finds that propofol, a well-known anesthesia medication, has a low occurrence of adverse events for children undergoing research-driven imaging studies. The study, led by a pediatric anesthesiologist now at Children's National Medical Center, showed a low incidence of adverse events and no long term complications when propofol was used to sedate children for imaging studies that require them to be still for long periods of time.

10 Jun 2010

Lantheus presents preliminary Phase 2 data of flurpiridaz F18 injection PET MPI at 57th SNM

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced preliminary Phase 2 data describing the methodology used to define an imaging protocol for a one-day rest-stress myocardial perfusion imaging test using its novel investigational PET imaging agent flurpiridaz F 18 injection (formerly known as BMS747158).

10 Jun 2010

TF2 bispecific antibody pretargeted therapy prolongs survival in animal model of human colonic cancer

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that pretargeted therapy with TF2, a bispecific antibody against carcinoembryonic antigen (CEA) and a small peptide, delayed tumor growth and prolonged survival in an animal model of human colonic cancer.

10 Jun 2010

Positive initial results from Nektar Therapeutics' NKTR-102 Phase 2 study for metastatic breast cancer

Nektar Therapeutics today announced positive preliminary initial results from a two-stage Phase 2 clinical study evaluating single-agent NKTR-102 in women with advanced/metastatic breast cancer patients who have received a prior taxane. The increased use of taxanes in breast cancer often renders tumors resistant to these drugs by the time the disease recurs, thereby underscoring the urgent need for new treatment options with novel mechanisms of action for metastatic disease.

10 Jun 2010

GE Healthcare presents interim phase 2 study results of fluciclatide

GE Healthcare, a unit of the General Electric Company, today presented interim phase 2 study results of fluciclatide, in collaboration with the National Cancer Institute, a federal research agency and part of the National Institutes of Health. Fluciclatide is an integrin-targeted radiopharmaceutical under development for oncology PET imaging.

10 Jun 2010

Imaging News and Research

Cintas issues tips for maintaining secure, compliant EMRs

McDermott's Health Industry Advisory Practice Group recognized as Health Team of the Year

TF12 antibody targets EGP-1 expressed in epithelial cancer: Immunomedics

Evidence-based review of TBI in sport

Children get MRI tests for reasons unrelated to benign anomalies: Study

National MS Society commits over $2.4M to support 7 CCSVI research projects

Olfactory function tests could help in treating patient in early stages of PD

HL survivors do not receive recommended cancer screening tests: Study

UT Southwestern first in North Texas to use dual-console DaVinci Surgical System

Protein IL-10 removes Escherichia coli K1 bacterium from blood and reverses brain damage

SBUMC uses RapidArc radiotherapy technology to treat cancer patients

New study demonstrates link between smoking and flat adenomas

DZNE, MRC and CIHR sign cooperation agreement for research on neurodegenerative diseases

Merge Healthcare launches CIMS workflow solution for imaging in clinical trials

Spectrum Dynamics commences ultra low dose trials of radiopharmaceutical agents with D-SPECT technology

New study finds propofol poses low risk for children undergoing research-driven imaging studies

Lantheus presents preliminary Phase 2 data of flurpiridaz F18 injection PET MPI at 57th SNM

TF2 bispecific antibody pretargeted therapy prolongs survival in animal model of human colonic cancer

Positive initial results from Nektar Therapeutics' NKTR-102 Phase 2 study for metastatic breast cancer

GE Healthcare presents interim phase 2 study results of fluciclatide

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News